Financials

News Discussions Technicals Forecast Seasonals

0LC7 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) operating, investing, and financing activities

0LC7 free cash flow for Q3 24 is -20.69 M USD. For 2023, 0LC7 free cash flow was -110.04 M USD and operating cash flow was -109.77 M USD.

Q4 '16

Q1 '17

Q2 '17

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: USD